Pembrolizumab Secures FDA Approval in Stomach Cancer

| October 12, 2017 | 0 Comments
Pembrolizumab Secures FDA Approval in Stomach Cancer

The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda®) for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply